Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX
Cynthia Mubanga, Mutale Mubanga, Obvious Nchimunya Chilyabanyama, Masauso Phiri, Caroline C Chisenga, Richard H Glashoff, Roma Chilengi · 2026
Read Evaluation of plasma anti-CS3 and anti-LTB IgG avidity among Zambian children vaccinated with ETVAX by Cynthia Mubanga, Mutale Mubanga, Obvious Nchimunya Chilyabanyama, Masauso Phiri, Caroline C Chisenga, Richard H Glashoff, Roma Chilengi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0335327.txt.
Description
Cynthia Mubanga and a team of researchers looked beyond simple antibody counts to judge a diarrhoea vaccine given to Zambian toddlers. The vaccine, ETVAX, targets a toxin-making E. coli that kills young children in poorer countries. Counts alone can mislead, so the team measured avidity, how tightly antibodies grip their target, in sixty children given three small doses over three months with a booster ingredient.
Blood taken before vaccination already showed gripping antibodies, evidence that these children had met the germ naturally. Surprisingly, grip strength against one target eased slightly by the end of the course rather than rising. The authors argue that vaccine trials in places where the germ circulates should weigh antibody quality alongside quantity, since natural exposure reshapes what the vaccine can add.
Catalog record
| CREATOR | Cynthia Mubanga, Mutale Mubanga, Obvious Nchimunya Chilyabanyama, Masauso Phiri, Caroline C Chisenga, Richard H Glashoff, Roma Chilengi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38821 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |